Hepatitis C New Drug Pipeline

New drugs in development for the treatment of hepatitis C

Updated 30 July 2010 -  Recent changes and additions are highlited 

 Drug Combinations - Specifically Targeted Antiviral Therapy For HCV (STAT-C)
 6 Projects

COMPANY	DRUG	Research	Preclin	Phase 1	Phase 2	Phase 3	NDA
Vertex trial status	Telaprevir (VX-950) Protease Inhibitor plus VX-222 Non-nucleoside Polymerase inhibitor w&wo Ribavirin and peginterferon
Bristol-Myers Squibb trial status - more	BMS-790052 NS5A Inhibitor plus BMS-650032 Protease Inhibitor w&wo Ribavirin and peginterferon
Gilead trial status	GS 9190 NN Polymerase Inhibitor plus GS 9256 Protease Inhibitor w&wo Ribavirin and peginterferon
Boehringer Ingelheim trial status	BI 201335 Protease Inhibitor plus BI 207127 Polymerase inhib. w&wo Ribavirin
Idenix trial status	IDX184 Nucleoside Polymerase Inhibitor plus IDX320 Protease Inhibitor
Hoffmann-La Roche trial status	R7128 (RO5024048) Nucleoside Polymerase Inhibitor plus ITMN-191 R7227 (RO5190591) Protease inhibitor

 Specifically Targeted Antiviral Therapy For HCV (STAT-C)
 Drugs That Directly Target The Hepatitis C Virus - 93 Projects

COMPANY	DRUG	Research	Preclin	Phase 1	Phase 2	Phase 3	NDA
Vertex	Telaprevir (VX-950) Protease Inhibitor
Vertex	VX-222 Non-nucleoside Polymerase inhibitor (from ViroChem Pharma)
Vertex	VX-985 Protease Inhibitor
Merck	Boceprevir (SCH503034) Protease inhibitor
Merck	Vaniprevir MK-7009 protease inhibitor
Sirna Therapeutics (aquired by Merck)	SIRNA-034 RNAi RNA interference
Isis / Merck	MK-0608 nucleoside polymerase inhib.
Intermune / Roche	Protease inhibitor ITMN-191 R7227 (RO5190591)
Intermune	2nd Gen. Protease inhibitor
Roche / Pharmasset	R7128 (RO5024048) nucleoside polymerase inhibitor
Roche / Ligand (Metabasis)	RG7348 nucleoside
Roche / Medivir	HCV polymerase inhibitor
Medivir / Tibotec / JnJ	TMC435 Protease inhibitor
Medivir / Tibotec / JnJ	polymerase inhibitor
Pfizer	PF-868554 Non-Nuc Polymerase inhibitor
Pfizer	PF-4878691
Tacere Bio / Benitec / Pfizer	RNA interference TT033
Boehringer Ingelheim	BI 201335 protease inhibitor
Boehringer Ingelheim	BI 207127 Polymerase inhib.
Intercell / Novartis	IC41 Therapeutic Vacccine
Bristol-Myers Squibb	BMS-790052 NS5A Inhibitor
Bristol-Myers Squibb	BMS-791325 Protease inhibitor
Bristol-Myers Squibb	BMS-650032 NS3 Inhibitor
Bristol-Myers Squibb	BMS-824393
Anadys	ANA598 Polymerase inhib
ViroChem Pharma (acquired by Vertex)	VCH-759 Non nuc Polymerase inhib	backup for VX-222
Globeimmune	GI 5005 Therapeutic Vaccine
iTherX (formerly Immusol)	ITX5061 Entry Inhibitor
iTherX	ITX4520 Entry Inhibitor
iTherX	Viral Envelop & Host Cell Receptor Entry Inhibitors
Idenix	IDX184 Nucleoside Polymerase Inhibitor
Idenix	Protease Inhibitor IDX320
Idenix	Non-Nuc Polymerase Inhibitor IDX375
Idenix	NS5A Inhibitors
Abbott	A-837093 Non-nuc polymerase inhib
Gilead	GS 9190 non-nuc polymerase inhibitor
Gilead	GS 9256 Protease Inhibitor
Gilead	Protease polymerase inhib
Achillion Gilead	ACH-1095 NS4A Antagonist
Achillion	ACH-1625 Protease inhibitor
Achillion	ACH-2684 Protease inhibitor
Achillion	ACH-2928 NS5A inhibitor
Presidio	PPI-461 NS5A inhibitor
Presidio	PPI-1301 NS5A inhibitor
Aethlon Medical	Hemopurifier
Transgene	TG4040 (MVA-HCV) Therapeutic Vaccine
Tripep / Inovio	Therapeutic Vaccine Chronvac-C
Arrow Therapeutics (aquired by AstraZeneca)	AZD7295 NS5A inhibitor
Arrow Therapeutics	Polymerase Inhibitor
Arrow Therapeutics	Protease Inhibitor
U of Mass. Med School	MBL-HCV1 human monoclonal antibody
Eiger BioPharmaceuticals	Clemizole NS4B-RNA Binding Inhibitor
Eiger BioPharmaceuticals	Amphipathic Helix Inhibitors
Santaris Pharma	SPC3649 Locked Nucleic Acid mRNA122 inhibitor
GENimmune (subsidiary of Innogenetics)	GNI-103 – Therapeutic vaccine
GENimmune	GNI-104 - monoclonal antibodie E1 protein
ChemDiv / IDialog	ID-12 small molecule
GlaxoSmithKline (Genelabs)	GSK625433 Polymerase Inhibitor
GlaxoSmithKline	Non-nucleoside & nucleoside polymerase inhib.
GenPhar	Vaccine
Abbott / Enanta	ABT-450 Protease inhib
Abbott	ABT-072 Non-Nucleoside Polymerase Inhibitor
Abbott	ABT-333 Non-Nucleoside Polymerase Inhibitor
Pharmasset	PSI-7977 nucleoside polymerase inhib.
Inhibitex	INX08189 Polymerase inhibitor
Pharmasset	PSI-938 nucleoside polymerase inhib.
Enanta	EDP-239 NS5A Polymerase Inhibitor
Enanta	Cyclophilin binder
Dynavax	Immunostimulatory sequences SD-101 Type C TLR9 agonist
Phenomix	protease inhibitor
Samaritan Pharmaceuticals	SP-30 entry inhibitor
Avila Therapeutics	AVL-181 protease inhibitor
Avila Therapeutics	AVL-192 protease inhibitor
Altor BioScience	Soluble T-cell Antigen Receptor
Arisyn Therapeutics	ATI-0810 (Formerly PG301029) RNA and protein production inhibitor
Progenics	PRO 206 entry inhibitor
BioWest (Migenix)	N-nucleoside Poly inhib	inactive
PTC / Merck (Schering)	IRES inhib
Vertex	Helicase inhibitor
Cetek	small molecule
Itherx (Immusol)/ Novartis	ITX2155 l
Argos Therapeutics	Therapeutic Vaccine
Tibotec	Polymerase inhib.
Regulus Therapeutics (Alnylam / Isis)GlaxoSmithKline	microRNA antagonism of miR-122
CombiMatrix	RNAi
Boehringer Ingelheim / Biota	Nucleoside analogues
BioLeap	????
Biotron	targeting HCV-p7
NanoViricides	HepaCide-I
Hanall	Antihepatitis agents
Astex Therapeutics	Enzyme Inhibitor
Avexa / TargetDrug	replication inhib.
StemCells Inc	HCV resistant Human liver engrafting cells
Vertex	VX-500 protease inhibitor
Vertex	VX-813 2nd gen protease inhibitor
Chiron / CSL	Therapeutic Vaccine CSL123
Biocryst	Polymerase inhibitor
ViRex Medical	Hepavaxx C Therapeutic Vaccine
Genmab	HuMax-HepC antibody
Protiva Biotherapeutics	siRNA
Phenomix	PHX1766 protease inhibitor

 Immune Modifiers and Other Non-specific Drugs - 37 Projects

COMPANY	DRUG	Research	Preclin	Phase 1	Phase 2	Phase 3	NDA
Human Genome Sciences	ZALBIN (Albuferon albinterferon alfa-2b) (interferon / albuminfusion)
SciClone Pharma	SCV-07 immunomodulator - STAT3 signaling inhibitor
Migenix	MX3235 Celgosivir alpha-glucosidase I inhibitor	inactive
Intarcia	Omega Interferon
NABI	Polyclonal antibody Civacir
Romark Laboratories	Alinia (Nitazoxanide)
Biolex / OctoPlus	Locteron controlled release interferon
Kemin Pharma	KPE02001003
Kemin Pharma	KPE00001113
VioQuest Pharmaceuticals	Lenocta (sodium stibogluconate SSG)
Conatus	CTS-1027 MMP inhibitor
Jenkin	JKB-122 antiinflammatory
Oklahoma University Health Sciences Center	Fluvastatin
Antipodean	Mito-Q antiinflammatory
Phynova	PYN17 antiviral anti-inflammatory anti-fibrotic
Canopus	CB5300 antiviral
Medtronic	continuous subcutaneous interferon external pump infusion system
Flamel Technologies	Medusa polymer controled release Interferon alpha-2b XL
Phynova	PYN18 anti viral plant extract
Can-Fite	CF102 antiinflammatory
Biotron	BIT225
Peregrine Pharm	Bavituximab
Amarillo Bioscience / CytoPharm	Low Dose Oral Interferon
Bristol-Myers Squibb (was owned by ZymoGenetics)	PEG-Interferon lambda
Novelos	NOV-205 immunomodulating and antiinflammatory
Scynexis	SCY-635 cyclophilin inhibitor
Idera	IMO-2125 TLR9 Agonist
Anadys	ANA773 TLR7 agonist
Debiopharm	Debio 025 Cyclophilin Inhibitor
Bristol-Myers Squibb / Ono	MDX-1106 (ONO-4538) anti-PD1
Cytheris	CYT107 Interleukin-7
Cubist	CB-183872 Protein therapeutic - Formerly IB657 (Illumigen Biosciences)
REPLICor	REP 9C broad-spectrum entry inhibitor
Nautilus	Oral Belerofon
Anadys	AN 025-1
Genodyssee	GEA007.1 IFN alpha variant
Alios BioPharma	Glycoferon
SciClone Pharma / Sigmatau	Zadaxin - thymalfasin
Bioenvision	Suvus
Enzo Biochem	Immune Regulator ECH18
Immunomedics	IMMU 105
Transition Therapeutics	IET Interferon Enhancing Therapy

• Text version of this table
• Discontinued Projects
• Forum

Some Hepatitis C Information and Support Links

• Hepatitis Central
• HepCBC
• MedHelp
• Hep-To-Date
• HepCnet
• HepC-Connection

Biotech information

• Biospace
• Signals
• Recap

Clinical trial information

• Center Watch
• NIHs ClinicalTrials.gov
• Trials Central
• SearchCinicalTrials.org

Studies and journal articles

• NIH PubMed Central
• National Library of Medicine
• Amedeo
• Plos Pathogens

Feedback, additions, errors? Comments?

Copyright, all rights reserved. This site is not affiliated in any way with any pharmaceutical company and does not endorse any treatment, product or investment. This information has been gathered from public sources, accuracy is not guaranteed. Please submit any comments, additions or corrections.